Menu
Back to Journals » Cancer Management and Research » Volume 11
c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients [Corrigendum]
Lin SH, Wang HK, Yeh KT, et al. Cancer Manag Res. 2019;11:5163–5169.
Following a review of the paper post-publication, the authors found two errors.
The authors advised that rstly, they incorrectly listed the CCH IRB number on page 5164. Therefore, the sentence “This study was approved by the Ethics Committees of Changhua Christian Hospital (Changhua, Taiwan), and we adhered to the guidelines approved by CCH IRB (no. 170143).” should instead read “This study was approved by the Ethics Committees of Changhua Christian Hospital (Changhua, Taiwan), and we adhered to the guidelines approved by CCH IRB (no. 170413).”
The authors advised that secondly, they incorrectly listed the wrong protein name in Table 3 on page 5167. This was the result of a typing error when they reviewed the manuscript. The title “The effect of clinicopathologic factor and UNC13C expression on mortality density and adjusted hazard ratio (aHR) among OSCC patients” should instead read “The effect of clinicopathologic factor and c-MYC expression on mortality density and adjusted hazard ratio (aHR) among OSCC patients.”
Read the original article
© 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.